Benitec Biopharma Inc. has released its financial results for the year ended June 30, 2025. The company reported no revenues for both 2025 and the prior year. Total operating expenses for 2025 were $41.8 million, up from $22.5 million in 2024. Research and development expenses increased to $18.3 million from $15.6 million in the previous year, mainly due to the ongoing clinical development of BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). General and administrative expenses saw a significant rise to $23.4 million from $7.0 million, primarily due to an increase in share-based compensation and various other operational costs. The company reported a loss from operations amounting to $41.8 million in 2025, compared to a loss of $22.5 million in 2024. Net loss attributable to shareholders was $37.9 million, compared to a net loss of $22.4 million in the previous year. As of June 30, 2025, Benitec Biopharma had $97.7 million in cash and cash equivalents. The company anticipates providing additional clinical study results for Cohort 1 Subjects in the fourth calendar quarter of this year.